Vivanza Biosciences Limited (BOM:530057)
India
· Delayed Price · Currency is INR 2.020
+0.090 (4.66%)
At close: Mar 10, 2026
Vivanza Biosciences Revenue
Vivanza Biosciences had revenue of 453.29M INR in the quarter ending December 31, 2025, with 2,900.30% growth. This brings the company's revenue in the last twelve months to 1.10B, up 870.71% year-over-year. In the fiscal year ending March 31, 2025, Vivanza Biosciences had annual revenue of 74.72M, down -73.21%.
Revenue (ttm)
1.10B
Revenue Growth
+870.71%
P/S Ratio
0.07
Revenue / Employee
137.71M
Employees
8
Market Cap
80.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 74.72M | -204.18M | -73.21% |
| Mar 31, 2024 | 278.89M | 97.35M | 53.62% |
| Mar 31, 2023 | 181.54M | 69.55M | 62.10% |
| Mar 31, 2022 | 111.99M | 12.60M | 12.67% |
| Mar 31, 2021 | 99.40M | 3.19M | 3.31% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ganga Pharmaceuticals | 26.93M |
| Unjha Formulations | 148.12M |
| Beryl Drugs | 176.65M |
| Decipher Labs | 148.66M |
| Brawn Biotech | 172.71M |
| Colinz Laboratories | 58.40M |
| Emmessar Biotech & Nutrition | 20.59M |
| Cian Healthcare | 232.80M |